STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma	Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm	Recruiting	Phase 2	2026-08-11		NCT06880523

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
AstraZeneca	806
Canadian Cancer Trials Group	73
National Cancer Institute, Naples	38

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Arthur J.E. Child Comprehensive Cancer Centre	Calgary	Canada	45
BCCA - Kelowna	Kelowna	Canada	10
BCCA - Vancouver	Vancouver	Canada	22
CHUM-Centre Hospitalier de l'Universite de Montreal	Montreal	Canada	20
Juravinski Cancer Centre at Hamilton Health Sciences	Hamilton	Canada	60
Kingston Health Sciences Centre	Kingston	Canada	91
London Health Sciences Centre Research Inc.	London	Canada	13
Ottawa Hospital Research Institute	Ottawa	Canada	46
Saskatoon Cancer Centre	Saskatoon	Canada	75
The Jewish General Hospital	Montreal	Canada	20
Trillium Health Partners - Credit Valley Hospital	Mississauga	Canada	10
University Health Network	Toronto	Canada	52
Waterloo Regional Health Network (WRHN)	Kitchener	Canada	6